Tislelizumab

About

Therapy type: Immunotherapy

Therapy strategy: PD-1/PD-L1 inhibition

Mappings

NCI Thesaurus: Tislelizumab (ncit:C121775)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Carboplatin, Pemetrexed, Tislelizumab
Sensitivity (+) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Cisplatin, Pemetrexed, Tislelizumab
Sensitivity (+) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
Sensitivity (+) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab
Sensitivity (+) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
Sensitivity (+) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab
Sensitivity (+) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab
Sensitivity (+) PD-L1 (TAP) >= 5% Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab
Sensitivity (+) PD-L1 (TAP) >= 5% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
Sensitivity (+) PD-L1 (TAP) >= 5% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab